Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Nonproliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)

Next Previous
X
Search
Trial Profile

A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Nonproliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 1467335 (Primary)
  • Indications Diabetic retinopathy
  • Focus Adverse reactions
  • Acronyms ROBIN Study
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 01 Jul 2024 Results assessing safety and efficacy of BI 1467335 in patients with non-proliferative diabetic retinopathy, published in the Eye.
    • 07 Sep 2020 According to a Boehringer Ingelheim Media Release, the company decided not to further develop BI 1467335 in this indication based on the lack of a clear efficacy signal and risk of dose dependent drug interactions of the compound in NPDR patients identified in another Phase I study.
    • 07 Sep 2020 Results presented in the Boehringer Ingelheim Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top